Spectral to present at Wedbush Life Sciences Conference

About this update from Spectral Medical Inc

[{"type":"text","content":"\n\n\nTORONTO, Aug. 1, 2013 /CNW/ - Spectral Diagnostics Inc., (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for\n patients with severe sepsis and septic shock, today announced that the\n Company's President and CEO, Dr. Paul Walker, will be presenting a\n corporate overview at the Wedbush Life Sciences Management Access\n Conference in New York on Wednesday, August 14, 2013, at 1:20 p.m. ET.\n\n\nA live webcast will be available on Spectral's website, www.spectraldx.com. The webcast will also be archived and available for replay for 90\n days.\n\n\nAbout Spectral Diagnostics\nSpectral is a Phase III company seeking U.S. FDA approval for its lead\n theranostics product for the treatment of severe sepsis and septic\n shock. Toraymyxin is a therapeutic hemoperfusion device that removes\n endotoxin, which can cause sepsis, from the bloodstream. Directed by\n the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared\n diagnostic for the risk of developing sepsis. Spectral's EUPHRATES\n trial is the world's first theranostics trial in the area of sepsis.\n\n\nToraymyxin has been approved for therapeutic use in Japan and Europe,\n and has been used safely and effectively on more than 100,000 patients\n to date. In March 2009, Spectral obtained the exclusive development and\n commercial rights in the U.S. for Toraymyxin, and in November 2010,\n signed an exclusive distribution agreement for this product in Canada.\n More than 350,000 patients are diagnosed with severe sepsis and septic\n shock in North America each year, representing a greater than $1\n billion market opportunity for Spectral. Spectral is listed on the\n Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the\n symbol DIAGF. For more information please visit www.spectraldx.com\n\nSOURCE: Spectral Diagnostics Inc.\n\n\n Anthony Businskas Executive Vice President and CFO 416-626-3233 ext. 2200 Adam Peeler Investor Relations TMX Equicom 416-815-0700 ext. [email protected] Copyright CNW Group 2013","length":3048,"tagName":"div"}]

More updates from Spectral Medical Inc